Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2663 results

Media Release / Jan 23, 2015
Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera
Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (…
Media Release / Jan 23, 2015
Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, a leading cause of bacterial meningitis in the US
With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a flexible…
Media Release / Jan 27, 2015
Novartis erzielt 2014 solide Umsatzsteigerungen, höhere Margen und Fortschritte in der Pipeline; mit der Umgestaltung des Portfolios fokussiert sich das Unternehmen auf führende Geschäftsbereiche
Wachstum des Nettoumsatzes im Jahr 2014 - mit starker Erhöhung der Kerngewinnmarge[1] Der Nettoumsatz steigt 2014 um 1% (+3% kWk[1])[2] auf USD 58,0 Milliarden (4. Quartal: -2%, +4% kWk) Das…
Media Release / Jan 27, 2015
Novartis a enregistré en 2014 une forte augmentation de ses ventes, sa marge et progrès de son pipeline; la transformation du portefeuille concentrera l'entreprise sur ses principales activités
Hausse du chiffre d'affaires net en 2014, avec une forte augmentation de la marge core[1] Hausse du chiffre d'affaires net de 1% (+3% tcc[1])[2] à USD 58,0 milliards en 2014 (-2%, +4% tcc au T4)…
Media Release / Jan 27, 2015
Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses
Net sales grew in FY 2014, with strong core[1] margin expansion Net sales increased 1% (+3% cc[1])[2] to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7…
Media Release / Feb 02, 2015
Alcon receives FDA approval of Pazeo(TM) Solution for ocular allergy itch relief
US Food and Drug Administration grants approval of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7% for sale in the United States Developed with efficacy data at 24 hours, post dose…
Media Release / Jan 28, 2015
Novartis announces study in NEJM showing Jakavi® was superior to standard therapy in rare blood cancer polycythemia vera
Jakavi® (ruxolitinib) treatment resulted in durable hematocrit control, spleen size reduction and symptom relief for patients with uncontrolled polycythemia vera[1] Polycythemia vera (PV) is…
Media Release / Feb 23, 2015
Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma
Farydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1] Farydak prolonged median…
Media Release / Feb 13, 2015
Novartis' heart failure medicine LCZ696 granted FDA priority review
Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] …
Media Release / Feb 27, 2015
Aktionäre genehmigen alle Anträge des Verwaltungsrats von Novartis
Aktionäre genehmigen für 2014 die 18. Dividendenerhöhung in Folge auf CHF 2,60 pro Aktie (+6%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats sowie alle weiteren Mitglieder des…